Test Bank for Ruppel’s Manual of Pulmonary Function Testing 1
b b b b b b b b b
2th Edition, By Mottram
b b b
Chapter 1 - 13 Updated
b b b b b
,Chapter 1: Indications for Pulmonary Function Testing Test Bank
b b b b b b b b
MULTIPLEbCHOICE
1. bWhobfirstbpopularizedbspirometrybforbthebevaluationbofbpulmonarybfunction?
a. AugustbandbMariebKrogh
b. AlvanbBarach
c. JohnbSeveringhaus
d. JohnbHutchinson
ANS:bD
HutchinsonbpopularizedbthebconceptbofbusingbVCbtobassessblungbfunction,bandbthebnamesbhebgavebto
bseveralbotherblungbcompartmentsbarebstillbusedbtoday.
DIF: 1 REF: p.b2 OBJ: Noneb MSC:bNBRC:bNone
2. Whichbofbthebfollowingbarebindicationsbforbperformingbspirometry?
1. Assessbthebriskbofblungbresection.
2. Determinebthebresponsebtobbronchodilatorbtherapy.
3. Assessbthebseveritybofbrestrictiveblungbdisease.
4. QuantifybthebextentbofbCOPD.
a. 1b andb 4
b. 2b andb 3
c. 1b,b2,bandb 4
d. 2b,b3,bandb 4
ANS:bC
Spirometrybcannotbassessbseveritybofbrestriction;bforbthatbyoubneedbtobmeasureblungbvolumesb(bseeb
Boxb1-2,bChapterb 1).
DIF: 1 REF: p.b7 OBJ: EL-2 MSC:bNBRC:bNone
,3. Thebmainbindicationbforbthebmeasurementbofblungbvolumesbisbtobdobwhichbofbthebfollowing?
a. Diagnoseborbassessbthebseveritybofbrestriction.
b. Evaluatebthebseveritybofbpulmonarybhypertension.
c. Determinebtheblevelbofbcardiopulmonarybfitness.
d. Assessbthebriskbofbabdominalbsurgicalbprocedures.
ANS:bA
Thebmostbcommonbreasonbforbmeasuringblungbvolumesbisbtobidentifybrestrictiveblungbdisease.bDIF:
1 REF: p.b35 OBJ: EL-2 MSC:bNBRC:bNone
4. DLCObmeasurementsbmaybbebindicatedbtobevaluatebpulmonarybinvolvementbinbwhichbofbthebfoll
owingbsystemicbdiseases?
a. Asthma
b. Sarcoidosis
c. Exertionalbhypoxemia
,Stuvia.comb-
bThebMarketplacebtobBuybandbSellbyourbStudybMaterial
d. Guillain-Barrébsyndrome
ANS:bB
Sarcoidosisbisbthebonlybsystemicbdiseaseblistedbthatbaffectsbgasbexchange.bDIF
:b1bREF:bp.b9b|bp.b19b|bp.b21b|bp.b35bOBJ:bEL-2bMSC:bNBRC:bNone
5. BloodbgasbanalysisbisbusedbwithbpatientsbwithbCOPDbtobdobwhichbofbthebfoll
owing?
a. Monitorbairwaybresponsiveness.
b. Determineblevelbofbcardiopulmonarybfitness.
c. Detectbpulmonarybhypertension.
d. AssessbneedbforbsupplementarybO2.
ANS:bD
Bloodbgasbanalysisbisbmostbcommonlybusedbtobdeterminebthebneedbforbsupplementalboxygenband
btobmanagebpatientsbwhobrequirebventilatorybsupport.
DIF: 2 REF: p.b15 OBJ: EL-
1bMSC:bNBRC:bCPFTb2A-2
6. Whichbofbthebfollowingbcausebemphysema?
1. 1-bAntitrypsinbdeficiency
2. Exposurebtobenvironmentalbpollutants
3. Radiationbtherapy
4. Cigarettebsmoking
a. 1b andb 2
b. 3b andb 4
c. 1b,b2,bandb 4
d. 2b,b3,bandb 4
ANS:bC
Emphysemabisbcausedbprimarilybbybcigarettebsmoking.bSomebemphysemabisbcausedbbybthebabsenc
ebofbabprotectivebenzyme.bChronicbexposurebtobenvironmentalbpollutantsbcanbalsobcontributebtobth
ebdevelopmentbofbemphysema.
DIF: 1 REF: p.b11 OBJ: EL-3b|bAL-2 MSC:bNBRC:bNone
7. Anbadultbpatientbcomplainsbofbchestbtightnessbandbcoughbwheneverbhebjogsbinbcoldbweather.bTh
esebsymptomsbarebconsistentbwithbwhichbofbthebfollowing?
a. Cysticbfibrosis
b. Asthma
c. Pulmonarybhypertension
d. Idiopathicbpulmonarybfibrosis
|
, ANS:bB
Agentsborbeventsbthatbcausebanbasthmaticbepisodebarebcalledbtriggersb(seebBoxb1-
7,bChapterb1).bAntigensbsuchbasbanimalbdander,bpollens,bandbdustsbarebthebmostbcommonbtrigger
s.bOtherbcommonbtriggersbincludebexposurebtobairbpollutantsbandbexercisebinbcoldborbdrybair.
DIF: 2 REF: p.b16 OBJ: EL-3 MSC:bNBRC:bNone
8. Whichbofbthebfollowingbstatementsbconcerningbtumorsbinbthebupperbairwaybisbtrue?
a. Therebmaybbebvariableborbfixedbobstruction.
b. Fixedbobstructionbwillbbebpresent.
c. Variablebobstructionbwillbbebpresent.
d. Smallbairwaybobstructionbwillbresult.
ANS:bA
Tumorsbinvolvingbthebupperbairwaybmaybcausebvariableborbfixedbobstruction.
DIF: 2 REF: p.b19 OBJ: EL-
2bMSC:bNBRC:bCPFTb3C-3
9. Sarcoidosisbisbabsystemicbdisorderbthatbusuallybcausesbwhichbofbthebfollowing?
a. Abrestrictivebventilatorybdefect
b. Anbobstructivebventilatorybdefect
c. Hyperreactivebairways
d. Primarybpulmonarybhypertension
ANS:bA
Restrictionbisboftenbassociatedbwithbthebfollowing:binterstitialblungbdiseases,bincludingbidiopathicbfib
rosis,bpneumoconioses,bandbsarcoidosis.
DIF: 1 REF: p.b19b|bp.b21 OBJ: EL-3 MSC:bNBRC:bNone
10. Forbwhichbofbthebfollowingbconditionsbmightbpulmonarybfunctionbtestingbbebcontraindicated?
a. Vocalbcordbdysfunction
b. Untreatedbpneumothorax
c. Congestivebheartbfailureb(CHF)
d. Bronchiolitisbobliterans
ANS:bB
Pulmonarybfunctionbtestsbarebusuallybcontraindicatedbinbthebpresencebofbpneumothorax.bHowever,
bundiagnosedbpneumothoraxbmaybpresentbabriskbifbpulmonarybfunctionbstudiesbarebperformed.
DIF: 1 REF: p.b23 OBJ: EL-
4bMSC:bNBRC:bCPFTb2B-6
d.
,11. Whichbofbthebfollowingbcorrectlybdescribe(s)bappropriatebphysicalbmeasurementsbbeforebp
ulmonarybfunctionbtesting?
1. Actualbbodybweightbshouldbbebusedbtobcalculatebpredictedbvalues.
2. Standingbheightbshouldbbebmeasuredbwhenbthebpatientbisbbarefoot.
3. Armbspanbshouldbbebusedbinsteadbofbheightbforbabpatientbwithbkyphosis.
4. Agebshouldbbebrecordedbtobthebnearestbdecadeb(10byearsb).
a. 1b only
b. 2b andb 3
c. 1b,b2,bandb 4
d. 1b,b2,b3,bandb 4
ANS:bB
Variousbphysicalbmeasurementsbarebrequiredbforbestimatingbeachbpatient’sbexpectedblevelbofbpul
monarybfunction.bAgebtobthebnearestbmonth,bheightbtobthebnearestb0.1bcm,bandbweightbarebusuallybr
ecordedbinbadditionbtobthebpatient’sbgender.bRaceborbethnicboriginbshouldbalsobbebrecorded.b(Alth
oughbbodybweightbisbrecorded,bitbisbnotbusedbtobcalculatebpredictedbvalues.)
DIF: 1 REF: p.b29 OBJ:
NonebMSC:bNBRC:bCPFTb3A-20
12. Inbadditionbtobexplainingbthebprocedurebforbeachbpulmonarybfunctionbtestbtobthebpatient,bthebp
ulmonarybfunctionbtechnologistbshouldbdobwhichbofbthebfollowing?
a. Brieflybexplainbthebphysiologicbbasisbofbthebtest.
b. Demonstratebthebcorrectbperformancebofbthebtestbmaneuver.
c. Limitbfeedbackbtobthebpatientbtobreducebthebplacebobeffect.
d. Explainbthebexactbnumberbofbeffortsbthatbwillbbebrequiredbforbeachbtest.
ANS:bB
Inbadditionbtobabdescriptionbofbthebtest,bthebmaneuverbshouldbalwaysbbebdemonstrated.
DIF: 1 REF: p.b32 OBJ:
NonebMSC:bNBRC:bCPFTb2B-6
13. Thebsingle-breathbdiffusingbcapacitybtestbwasbfirstbdescribedbby:
a. JohnbSeveringhaus
b. AugustbandbMariebKrogh
c. RobertbHyatt
d. LelandbClark
ANS:bB
Thebbasisbforbthebmodernbsingle-
breathbdiffusingbcapacityb(DLCO)btestbwasbdescribedbbybAugustbandbMariebKroghbinb1911.
DIF: 1 REF: p.b5 OBJ: Noneb MSC:bNBRC:bNone
|
,Stuvia.comb-
bThebMarketplacebtobBuybandbSellbyourbStudybMaterial
14. DLCObmeasurementsbmaybbebindicatedbtobevaluatebgasbexchangebabnormalitybinbwhichbofbt
hebfollowing?
a. Ketoacidosis
b. Myastheniabgravis
c. Interstitialblungbdisease
d. Bronchitis
ANS:bC
Thebotherboptionsbdobnotbaffectbthebalveolarbcapillarybmembranebinterface.b
DIF: 1 REF: p.b9 OBJ: EL-2 MSC:bNBRC:bNone
15. Vocalbcordbdysfunctionbwillbtypicallybaffectbthebflow-volumebloopbinbwhatbway?
a. Bluntbthebexpiratorybportionbofbthebcurve
b. Bluntbbothbthebinspiratorybandbexpiratorybportionsbofbthebcurve
c. Bluntbthebinspiratorybportionbofbthebcurve
Havebnobeffectbonbthebcurvebbutbcausebinspiratorybstridor
d.
Downloadedbby:bSuperAb|
fbthisbdocumentbisbillegal
, Stuvia.comb-
bThebMarketplacebtobBuybandbSellbyourbStudybMaterial
ANS:
C
Thebvocalbcordsbarebnormallybheldbopenborbabductedbduringbinspiration.bWhenbdamaged,bthebv
ocalbcordsbmovebtowardbthebmidline,bnarrowingbthebairwaybopening.bThisbtypebofbobstructionbli
mitsbflowbprimarilybduringbinspiration.
DIF: 2 REF: p.b18 OBJ: EL-
4bMSC:bNBRC:bCPFTb3C-3
16. Allbofbthebfollowingbdiseasebprocessesbarebpotentialbcausesbofbabrestrictivebpatternbexcept:
a. Interstitialblungbdiseaseb(e.g.,bfibrosis,bsarcoidosis)
b. Kyphoscoliosis
c. Asthma
d. Neuromuscularbdisorders
ANS:bC
Asthmabcausesbairwaybobstruction.
DIF: 1 REF: p.b21b|bp.b22b|bp.b23 OBJ: EL-
3bMSC:bNBRC:bNone
17. Thebfollowingbdatabarebobtainedbfrombabsubjectbcomplainingbofbshortnessbofbbreath:
Predicted Found %bPred
TLCpl 5.76 3.18 55
RVpl 2.38 1.18 50
FVC 3.38 2.10 62
FEV1 2.63 1.88 71
FEV1/FVC 78 89
DLCO 23.1 6.0 26
Thesebdatabarebmostbconsistentbwithbwhichbdiseasebentity?
a. Pulmonarybfibrosis
b. Kyphoscoliosis
c. Obesity
d. Emphysema
ANS:bA
Excerptbfrombthebrestrictivebdiseasebdiscussion:bThesebreductionsbinbVCbandbTLCboccurbasbfibrosisbc
ausesbtheblungsbtobbecomebstiff.bPulmonarybfibrosisbisbthebonlybdiseasebentityblistedbthatbcausesbabr
eductionbinblungbvolumesbandbaffectsbthebalveolarbcapillarybinterfaceb(e.g.,breducedbDLCO).
DIF: 3 REF: p.b20 OBJ: EL-3
d.
, Stuvia.comb-
bThebMarketplacebtobBuybandbSellbyourbStudybMaterial
ANS:
MSC:bNBRC:bRPFTb3C-4b
18. LoubGehrig,babfamousbNewbYorkbYankeebbaseballbplayer,bisboftenbassociatedbwithbwhichbne
uromuscularbdisease?
a. Amyotrophicblateralbsclerosis
b. Guillain-Barrébsyndrome
c. Diaphragmbparalysisbsyndromeb
Myastheniabgravis
A
Amyotrophicblateralbsclerosisb(ALS,borbLoubGehrig’sbdisease)baffectsbthebanteriorbhornbcellsbofbth
ebspinalbcordb(motorbneurons).
DIF: 1 REF: p.b24 OBJ: EL-3 MSC:bNBRC:bNone
19. Thebfollowingbdatabarebobtainedbfrombabsubjectbcomplainingbofbshortnessbofbbreath:
Predicted Found %bPred
TLCpl 6.59 4.12 63
RVpl 2.43 3.01 124
FVC 4.16 1.14 28
FEV1 3.16 1.16 37
FEV1/FVC 76 99
MEP +190 63 33
MIP -101 -56 55
Thesebdatabarebmostbconsistentbwithbwhichbdiseasebentity?
a. Obesity
b. Pectusbexcavatum
c. Pulmonarybfibrosis
d. Myastheniabgravis
ANS:bD
ProgressionbofbabmyasthenicbcrisisbcanbbebassessedbusingbVCbandbrespiratorybpressures.bResul
tsbwouldbyieldbabreductionbinblungbvolumesbandbrespiratorybmusclebpressures,basbseenbinbthisbca
se.
DIF: 3 REF: p.b24 OBJ: EL-
3bMSC:bNBRC:bRPFTb3C-4b
20. Allbofbthebfollowingbpulmonarybfunctionbtestsbmaybbebusedbtobfollowbthebeffectbofbtreatmentbfor
bcongestivebheartbfailurebexcept:
a. Lungbvolumes
d.
, ANS:
b. Arterialbbloodbgases
c. Diffusingbcapacity
d. Maximalbrespiratorybpressures
ANS:bD
Pulmonarybfunctionbtests,bparticularlyblungbvolumesbandbDLCO,bmaybbebusedbtobmonitorbthebeffe
ctsbofbtreatment.bArterialbbloodbgasesbmaybalsobassistbinbassessingbgasbexchange,bbutbthebrespi
ratorybmusclesbarebnotbaffected.
DIF: 2 REF: p.b25 OBJ: EL-4 MSC:bNBRC:bNone
21. Allbofbthebfollowingbanthropometricbmeasurementsbarebessentialbforbpulmonarybfunctionbtes
tingbexcept:
a. Height
b. Percentbbodybfat
c. Gende
rbAge
B
Age,bheight,bandbweightbarebusuallybrecordedbinbadditionbtobthebpatient’sbsex.bRaceborbethnicbo
riginbshouldbalsobbebrecorded.
DIF: 1 REF: p.b29 OBJ:
NonebMSC:bNBRC:bCPFTb3A-20
22. TherebarebthreebessentialbcomponentsbtobanbFVCbmaneuver.bWhichbofbthebfollowingbisbthebfirs
tbphasebofbthebmaneuver?
a. AbdeepbbreathbtobTLC
b. ContinuedbexhalationbtobRV
c. Thebinitialbblastbofbinspiratorybbreathbafterbemptyingbtheblungsbfully
ANS:bA
AccordingbtobthebAmericanbThoracicbSociety-EuropeanbRespiratorybSocietyb(ATS-
ERS)bguidelines,bthebfirstbimportantbportionbofbthebmaneuverbisbthebdeepbbreathbtobTLCbbeforebtheb
initialbblast.
DIF: 1 REF: p.b31 OBJ:
NonebMSC:bNBRC:bCPFTb2A-6
23. AccordingbtobthebATS-
ERSbgeneralbconsiderationsbguidelines,ballbofbthebfollowingbshouldbbebavoidedbbeforeblungbfunc
tionbtestingbexcept:
a. Smokingbwithinb1bhourbofbtesting
b. Wearingbrestrictivebclothing
c. Eatingbablargebmealbwithinb2bhoursbofbtesting
|
b b b b b b b b b
2th Edition, By Mottram
b b b
Chapter 1 - 13 Updated
b b b b b
,Chapter 1: Indications for Pulmonary Function Testing Test Bank
b b b b b b b b
MULTIPLEbCHOICE
1. bWhobfirstbpopularizedbspirometrybforbthebevaluationbofbpulmonarybfunction?
a. AugustbandbMariebKrogh
b. AlvanbBarach
c. JohnbSeveringhaus
d. JohnbHutchinson
ANS:bD
HutchinsonbpopularizedbthebconceptbofbusingbVCbtobassessblungbfunction,bandbthebnamesbhebgavebto
bseveralbotherblungbcompartmentsbarebstillbusedbtoday.
DIF: 1 REF: p.b2 OBJ: Noneb MSC:bNBRC:bNone
2. Whichbofbthebfollowingbarebindicationsbforbperformingbspirometry?
1. Assessbthebriskbofblungbresection.
2. Determinebthebresponsebtobbronchodilatorbtherapy.
3. Assessbthebseveritybofbrestrictiveblungbdisease.
4. QuantifybthebextentbofbCOPD.
a. 1b andb 4
b. 2b andb 3
c. 1b,b2,bandb 4
d. 2b,b3,bandb 4
ANS:bC
Spirometrybcannotbassessbseveritybofbrestriction;bforbthatbyoubneedbtobmeasureblungbvolumesb(bseeb
Boxb1-2,bChapterb 1).
DIF: 1 REF: p.b7 OBJ: EL-2 MSC:bNBRC:bNone
,3. Thebmainbindicationbforbthebmeasurementbofblungbvolumesbisbtobdobwhichbofbthebfollowing?
a. Diagnoseborbassessbthebseveritybofbrestriction.
b. Evaluatebthebseveritybofbpulmonarybhypertension.
c. Determinebtheblevelbofbcardiopulmonarybfitness.
d. Assessbthebriskbofbabdominalbsurgicalbprocedures.
ANS:bA
Thebmostbcommonbreasonbforbmeasuringblungbvolumesbisbtobidentifybrestrictiveblungbdisease.bDIF:
1 REF: p.b35 OBJ: EL-2 MSC:bNBRC:bNone
4. DLCObmeasurementsbmaybbebindicatedbtobevaluatebpulmonarybinvolvementbinbwhichbofbthebfoll
owingbsystemicbdiseases?
a. Asthma
b. Sarcoidosis
c. Exertionalbhypoxemia
,Stuvia.comb-
bThebMarketplacebtobBuybandbSellbyourbStudybMaterial
d. Guillain-Barrébsyndrome
ANS:bB
Sarcoidosisbisbthebonlybsystemicbdiseaseblistedbthatbaffectsbgasbexchange.bDIF
:b1bREF:bp.b9b|bp.b19b|bp.b21b|bp.b35bOBJ:bEL-2bMSC:bNBRC:bNone
5. BloodbgasbanalysisbisbusedbwithbpatientsbwithbCOPDbtobdobwhichbofbthebfoll
owing?
a. Monitorbairwaybresponsiveness.
b. Determineblevelbofbcardiopulmonarybfitness.
c. Detectbpulmonarybhypertension.
d. AssessbneedbforbsupplementarybO2.
ANS:bD
Bloodbgasbanalysisbisbmostbcommonlybusedbtobdeterminebthebneedbforbsupplementalboxygenband
btobmanagebpatientsbwhobrequirebventilatorybsupport.
DIF: 2 REF: p.b15 OBJ: EL-
1bMSC:bNBRC:bCPFTb2A-2
6. Whichbofbthebfollowingbcausebemphysema?
1. 1-bAntitrypsinbdeficiency
2. Exposurebtobenvironmentalbpollutants
3. Radiationbtherapy
4. Cigarettebsmoking
a. 1b andb 2
b. 3b andb 4
c. 1b,b2,bandb 4
d. 2b,b3,bandb 4
ANS:bC
Emphysemabisbcausedbprimarilybbybcigarettebsmoking.bSomebemphysemabisbcausedbbybthebabsenc
ebofbabprotectivebenzyme.bChronicbexposurebtobenvironmentalbpollutantsbcanbalsobcontributebtobth
ebdevelopmentbofbemphysema.
DIF: 1 REF: p.b11 OBJ: EL-3b|bAL-2 MSC:bNBRC:bNone
7. Anbadultbpatientbcomplainsbofbchestbtightnessbandbcoughbwheneverbhebjogsbinbcoldbweather.bTh
esebsymptomsbarebconsistentbwithbwhichbofbthebfollowing?
a. Cysticbfibrosis
b. Asthma
c. Pulmonarybhypertension
d. Idiopathicbpulmonarybfibrosis
|
, ANS:bB
Agentsborbeventsbthatbcausebanbasthmaticbepisodebarebcalledbtriggersb(seebBoxb1-
7,bChapterb1).bAntigensbsuchbasbanimalbdander,bpollens,bandbdustsbarebthebmostbcommonbtrigger
s.bOtherbcommonbtriggersbincludebexposurebtobairbpollutantsbandbexercisebinbcoldborbdrybair.
DIF: 2 REF: p.b16 OBJ: EL-3 MSC:bNBRC:bNone
8. Whichbofbthebfollowingbstatementsbconcerningbtumorsbinbthebupperbairwaybisbtrue?
a. Therebmaybbebvariableborbfixedbobstruction.
b. Fixedbobstructionbwillbbebpresent.
c. Variablebobstructionbwillbbebpresent.
d. Smallbairwaybobstructionbwillbresult.
ANS:bA
Tumorsbinvolvingbthebupperbairwaybmaybcausebvariableborbfixedbobstruction.
DIF: 2 REF: p.b19 OBJ: EL-
2bMSC:bNBRC:bCPFTb3C-3
9. Sarcoidosisbisbabsystemicbdisorderbthatbusuallybcausesbwhichbofbthebfollowing?
a. Abrestrictivebventilatorybdefect
b. Anbobstructivebventilatorybdefect
c. Hyperreactivebairways
d. Primarybpulmonarybhypertension
ANS:bA
Restrictionbisboftenbassociatedbwithbthebfollowing:binterstitialblungbdiseases,bincludingbidiopathicbfib
rosis,bpneumoconioses,bandbsarcoidosis.
DIF: 1 REF: p.b19b|bp.b21 OBJ: EL-3 MSC:bNBRC:bNone
10. Forbwhichbofbthebfollowingbconditionsbmightbpulmonarybfunctionbtestingbbebcontraindicated?
a. Vocalbcordbdysfunction
b. Untreatedbpneumothorax
c. Congestivebheartbfailureb(CHF)
d. Bronchiolitisbobliterans
ANS:bB
Pulmonarybfunctionbtestsbarebusuallybcontraindicatedbinbthebpresencebofbpneumothorax.bHowever,
bundiagnosedbpneumothoraxbmaybpresentbabriskbifbpulmonarybfunctionbstudiesbarebperformed.
DIF: 1 REF: p.b23 OBJ: EL-
4bMSC:bNBRC:bCPFTb2B-6
d.
,11. Whichbofbthebfollowingbcorrectlybdescribe(s)bappropriatebphysicalbmeasurementsbbeforebp
ulmonarybfunctionbtesting?
1. Actualbbodybweightbshouldbbebusedbtobcalculatebpredictedbvalues.
2. Standingbheightbshouldbbebmeasuredbwhenbthebpatientbisbbarefoot.
3. Armbspanbshouldbbebusedbinsteadbofbheightbforbabpatientbwithbkyphosis.
4. Agebshouldbbebrecordedbtobthebnearestbdecadeb(10byearsb).
a. 1b only
b. 2b andb 3
c. 1b,b2,bandb 4
d. 1b,b2,b3,bandb 4
ANS:bB
Variousbphysicalbmeasurementsbarebrequiredbforbestimatingbeachbpatient’sbexpectedblevelbofbpul
monarybfunction.bAgebtobthebnearestbmonth,bheightbtobthebnearestb0.1bcm,bandbweightbarebusuallybr
ecordedbinbadditionbtobthebpatient’sbgender.bRaceborbethnicboriginbshouldbalsobbebrecorded.b(Alth
oughbbodybweightbisbrecorded,bitbisbnotbusedbtobcalculatebpredictedbvalues.)
DIF: 1 REF: p.b29 OBJ:
NonebMSC:bNBRC:bCPFTb3A-20
12. Inbadditionbtobexplainingbthebprocedurebforbeachbpulmonarybfunctionbtestbtobthebpatient,bthebp
ulmonarybfunctionbtechnologistbshouldbdobwhichbofbthebfollowing?
a. Brieflybexplainbthebphysiologicbbasisbofbthebtest.
b. Demonstratebthebcorrectbperformancebofbthebtestbmaneuver.
c. Limitbfeedbackbtobthebpatientbtobreducebthebplacebobeffect.
d. Explainbthebexactbnumberbofbeffortsbthatbwillbbebrequiredbforbeachbtest.
ANS:bB
Inbadditionbtobabdescriptionbofbthebtest,bthebmaneuverbshouldbalwaysbbebdemonstrated.
DIF: 1 REF: p.b32 OBJ:
NonebMSC:bNBRC:bCPFTb2B-6
13. Thebsingle-breathbdiffusingbcapacitybtestbwasbfirstbdescribedbby:
a. JohnbSeveringhaus
b. AugustbandbMariebKrogh
c. RobertbHyatt
d. LelandbClark
ANS:bB
Thebbasisbforbthebmodernbsingle-
breathbdiffusingbcapacityb(DLCO)btestbwasbdescribedbbybAugustbandbMariebKroghbinb1911.
DIF: 1 REF: p.b5 OBJ: Noneb MSC:bNBRC:bNone
|
,Stuvia.comb-
bThebMarketplacebtobBuybandbSellbyourbStudybMaterial
14. DLCObmeasurementsbmaybbebindicatedbtobevaluatebgasbexchangebabnormalitybinbwhichbofbt
hebfollowing?
a. Ketoacidosis
b. Myastheniabgravis
c. Interstitialblungbdisease
d. Bronchitis
ANS:bC
Thebotherboptionsbdobnotbaffectbthebalveolarbcapillarybmembranebinterface.b
DIF: 1 REF: p.b9 OBJ: EL-2 MSC:bNBRC:bNone
15. Vocalbcordbdysfunctionbwillbtypicallybaffectbthebflow-volumebloopbinbwhatbway?
a. Bluntbthebexpiratorybportionbofbthebcurve
b. Bluntbbothbthebinspiratorybandbexpiratorybportionsbofbthebcurve
c. Bluntbthebinspiratorybportionbofbthebcurve
Havebnobeffectbonbthebcurvebbutbcausebinspiratorybstridor
d.
Downloadedbby:bSuperAb|
fbthisbdocumentbisbillegal
, Stuvia.comb-
bThebMarketplacebtobBuybandbSellbyourbStudybMaterial
ANS:
C
Thebvocalbcordsbarebnormallybheldbopenborbabductedbduringbinspiration.bWhenbdamaged,bthebv
ocalbcordsbmovebtowardbthebmidline,bnarrowingbthebairwaybopening.bThisbtypebofbobstructionbli
mitsbflowbprimarilybduringbinspiration.
DIF: 2 REF: p.b18 OBJ: EL-
4bMSC:bNBRC:bCPFTb3C-3
16. Allbofbthebfollowingbdiseasebprocessesbarebpotentialbcausesbofbabrestrictivebpatternbexcept:
a. Interstitialblungbdiseaseb(e.g.,bfibrosis,bsarcoidosis)
b. Kyphoscoliosis
c. Asthma
d. Neuromuscularbdisorders
ANS:bC
Asthmabcausesbairwaybobstruction.
DIF: 1 REF: p.b21b|bp.b22b|bp.b23 OBJ: EL-
3bMSC:bNBRC:bNone
17. Thebfollowingbdatabarebobtainedbfrombabsubjectbcomplainingbofbshortnessbofbbreath:
Predicted Found %bPred
TLCpl 5.76 3.18 55
RVpl 2.38 1.18 50
FVC 3.38 2.10 62
FEV1 2.63 1.88 71
FEV1/FVC 78 89
DLCO 23.1 6.0 26
Thesebdatabarebmostbconsistentbwithbwhichbdiseasebentity?
a. Pulmonarybfibrosis
b. Kyphoscoliosis
c. Obesity
d. Emphysema
ANS:bA
Excerptbfrombthebrestrictivebdiseasebdiscussion:bThesebreductionsbinbVCbandbTLCboccurbasbfibrosisbc
ausesbtheblungsbtobbecomebstiff.bPulmonarybfibrosisbisbthebonlybdiseasebentityblistedbthatbcausesbabr
eductionbinblungbvolumesbandbaffectsbthebalveolarbcapillarybinterfaceb(e.g.,breducedbDLCO).
DIF: 3 REF: p.b20 OBJ: EL-3
d.
, Stuvia.comb-
bThebMarketplacebtobBuybandbSellbyourbStudybMaterial
ANS:
MSC:bNBRC:bRPFTb3C-4b
18. LoubGehrig,babfamousbNewbYorkbYankeebbaseballbplayer,bisboftenbassociatedbwithbwhichbne
uromuscularbdisease?
a. Amyotrophicblateralbsclerosis
b. Guillain-Barrébsyndrome
c. Diaphragmbparalysisbsyndromeb
Myastheniabgravis
A
Amyotrophicblateralbsclerosisb(ALS,borbLoubGehrig’sbdisease)baffectsbthebanteriorbhornbcellsbofbth
ebspinalbcordb(motorbneurons).
DIF: 1 REF: p.b24 OBJ: EL-3 MSC:bNBRC:bNone
19. Thebfollowingbdatabarebobtainedbfrombabsubjectbcomplainingbofbshortnessbofbbreath:
Predicted Found %bPred
TLCpl 6.59 4.12 63
RVpl 2.43 3.01 124
FVC 4.16 1.14 28
FEV1 3.16 1.16 37
FEV1/FVC 76 99
MEP +190 63 33
MIP -101 -56 55
Thesebdatabarebmostbconsistentbwithbwhichbdiseasebentity?
a. Obesity
b. Pectusbexcavatum
c. Pulmonarybfibrosis
d. Myastheniabgravis
ANS:bD
ProgressionbofbabmyasthenicbcrisisbcanbbebassessedbusingbVCbandbrespiratorybpressures.bResul
tsbwouldbyieldbabreductionbinblungbvolumesbandbrespiratorybmusclebpressures,basbseenbinbthisbca
se.
DIF: 3 REF: p.b24 OBJ: EL-
3bMSC:bNBRC:bRPFTb3C-4b
20. Allbofbthebfollowingbpulmonarybfunctionbtestsbmaybbebusedbtobfollowbthebeffectbofbtreatmentbfor
bcongestivebheartbfailurebexcept:
a. Lungbvolumes
d.
, ANS:
b. Arterialbbloodbgases
c. Diffusingbcapacity
d. Maximalbrespiratorybpressures
ANS:bD
Pulmonarybfunctionbtests,bparticularlyblungbvolumesbandbDLCO,bmaybbebusedbtobmonitorbthebeffe
ctsbofbtreatment.bArterialbbloodbgasesbmaybalsobassistbinbassessingbgasbexchange,bbutbthebrespi
ratorybmusclesbarebnotbaffected.
DIF: 2 REF: p.b25 OBJ: EL-4 MSC:bNBRC:bNone
21. Allbofbthebfollowingbanthropometricbmeasurementsbarebessentialbforbpulmonarybfunctionbtes
tingbexcept:
a. Height
b. Percentbbodybfat
c. Gende
rbAge
B
Age,bheight,bandbweightbarebusuallybrecordedbinbadditionbtobthebpatient’sbsex.bRaceborbethnicbo
riginbshouldbalsobbebrecorded.
DIF: 1 REF: p.b29 OBJ:
NonebMSC:bNBRC:bCPFTb3A-20
22. TherebarebthreebessentialbcomponentsbtobanbFVCbmaneuver.bWhichbofbthebfollowingbisbthebfirs
tbphasebofbthebmaneuver?
a. AbdeepbbreathbtobTLC
b. ContinuedbexhalationbtobRV
c. Thebinitialbblastbofbinspiratorybbreathbafterbemptyingbtheblungsbfully
ANS:bA
AccordingbtobthebAmericanbThoracicbSociety-EuropeanbRespiratorybSocietyb(ATS-
ERS)bguidelines,bthebfirstbimportantbportionbofbthebmaneuverbisbthebdeepbbreathbtobTLCbbeforebtheb
initialbblast.
DIF: 1 REF: p.b31 OBJ:
NonebMSC:bNBRC:bCPFTb2A-6
23. AccordingbtobthebATS-
ERSbgeneralbconsiderationsbguidelines,ballbofbthebfollowingbshouldbbebavoidedbbeforeblungbfunc
tionbtestingbexcept:
a. Smokingbwithinb1bhourbofbtesting
b. Wearingbrestrictivebclothing
c. Eatingbablargebmealbwithinb2bhoursbofbtesting
|
